RETA
$20.00
Chain: 39–amino acid triple agonist of GLP-1, GIP & glucagon receptors.
Research focus: Enhances energy expenditure and metabolic rate in models of obesity.
Studies: NEJM 2023 phase 2 data showed up to 24% body-weight reduction after 48 weeks.
Highlights: Studied for its effects on weight loss and improved glucose and lipid metabolism.
Disclaimer: For research purposes only.